ARVN (Arvinas) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


ARVN Arvinas Inc ARVN
70 GF Score
Price $8.03
GF Value $11.80
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arvinas Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Arvinas's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ARVN vs EIKN, GYRE, TECX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Arvinas's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arvinas Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Arvinas's Margin of Safety % (DCF FCF Based) falls into.


ARVN
70GF Score
Arvinas Inc ARVN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.03 is trading 31.9% below its estimated GF Value™ of $11.80. GuruFocus considers Arvinas to be Possible Value Trap.

Key valuation signals for ARVN:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $11.80 vs. price of $8.03 (31.9% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
70GF Score

Get the complete analysis for ARVN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.03
Price
$11.80
GF Value